Section[removed]k) Summary K Number -K14 APR[removed]

First Page		Document Content
Date: 2014-05-07 12:37:00 Dosage forms Food law Pharmacology Infusion set Premarket approval Infusion pump Federal Food Drug and Cosmetic Act Medical device Subcutaneous injection Medicine Medical equipment Food and Drug Administration		Section[removed]k) Summary K Number -K14 APR[removed] Add to Reading List Source URL: www.accessdata.fda.gov Download Document from Source Website File Size: 201,31 KB Share Document on Facebook

	Medication Guide ZINBRYTA™ (zin-bry-tuh) (daclizumab) injection, for subcutaneous use What is the most important information I should know about ZINBRYTA? ZINBRYTA can cause serious side effects, including: DocID: 1t3jF - View Document
	Microsoft PowerPoint - M wound-certifi Kim & Carol.ppt [Compatibility Mode] DocID: 1osGd - View Document
	Medication Guide CIMZIA® (CIM-zee-uh) (certolizumab pegol) lyophilized powder or solution for subcutaneous use Read the Medication Guide that comes with CIMZIA before you start using it, and before each injection of CIM DocID: 1aimb - View Document
	MEDICATION GUIDE PegIntron® (peg-In-tron) (Peginterferon alfa-2b) for injection, for subcutaneous use Read this Medication Guide before you start taking PegIntron®, and each time you get a refill. There may be new info DocID: 19wF3 - View Document
	Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of M118, a Novel Rationally Engineered Low Molecular Weight Heparin Given as a Subcutaneous Injection in a Rising Dose Cohort Regimen in Healthy Subjects S. Bou DocID: 19tt1 - View Document